207 related articles for article (PubMed ID: 23994841)
1. Can effluent matrix metalloproteinase 2 and plasminogen activator inhibitor 1 be used as biomarkers of peritoneal membrane alterations in peritoneal dialysis patients?
Barreto DL; Coester AM; Struijk DG; Krediet RT
Perit Dial Int; 2013; 33(5):529-37. PubMed ID: 23994841
[TBL] [Abstract][Full Text] [Related]
2. Peritoneal effluent MMP-2 and PAI-1 in encapsulating peritoneal sclerosis.
Lopes Barreto D; Struijk DG; Krediet RT
Am J Kidney Dis; 2015 May; 65(5):748-53. PubMed ID: 25530106
[TBL] [Abstract][Full Text] [Related]
3. Early Detection of Imminent Encapsulating Peritoneal Sclerosis: Free Water Transport, Selected Effluent Proteins, or Both?
Barreto DL; Sampimon DE; Struijk DG; Krediet RT
Perit Dial Int; 2019; 39(1):83-89. PubMed ID: 30478138
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal Changes of PAI-1, MMP-2, and VEGF in Peritoneal Effluents and Their Associations with Peritoneal Small-Solute Transfer Rate in New Peritoneal Dialysis Patients.
Hao N; Chiou TT; Wu CH; Lei YY; Liang PL; Chao MC; Yang H; Chen JB
Biomed Res Int; 2019; 2019():2152584. PubMed ID: 31192253
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor-1 and peritoneal transport in diabetic and non-diabetic peritoneal dialysis patients.
Lin JJ; Parton L; Bereket G; Wadhwa NK
Clin Nephrol; 1995 Nov; 44(5):310-5. PubMed ID: 8605711
[TBL] [Abstract][Full Text] [Related]
6. Effects of glucose and plasminogen activator inhibitor-1 on collagen metabolism in the peritoneum.
Higuchi C; Tanihata Y; Nishimura H; Naito T; Sanaka T
Ther Apher Dial; 2005 Apr; 9(2):173-81. PubMed ID: 15828931
[TBL] [Abstract][Full Text] [Related]
7. Higher Dialysate Matrix Metalloproteinase-2 Levels Are Associated with Peritoneal Membrane Dysfunction.
Cho Y; Johnson DW; Vesey DA; Hawley CM; Pascoe EM; Clarke M; Topley N;
Perit Dial Int; 2016; 36(1):16-25. PubMed ID: 25292407
[TBL] [Abstract][Full Text] [Related]
8. What does the dialysate level of matrix metalloproteinase 2 tell us?
Ertilav M; Timur O; Hür E; Bozkurt D; Nar H; Kologlu T; Sen S; Duman S
Adv Perit Dial; 2011; 27():6-10. PubMed ID: 22073820
[TBL] [Abstract][Full Text] [Related]
9. Correlations between plasminogen activator inhibitor-1 and peritoneal transport in pediatric CCPD patients.
Lin JJ; Singhal K; Parton L; Cascio C; Patlak CS; Stewart CL
Perit Dial Int; 1995; 15(6):246-51. PubMed ID: 7578502
[TBL] [Abstract][Full Text] [Related]
10. Peritoneal changes in patients on long-term peritoneal dialysis.
Krediet RT; Struijk DG
Nat Rev Nephrol; 2013 Jul; 9(7):419-29. PubMed ID: 23670085
[TBL] [Abstract][Full Text] [Related]
11. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis--a multicentre study in Japan.
Hirahara I; Inoue M; Okuda K; Ando Y; Muto S; Kusano E
Nephrol Dial Transplant; 2007 Feb; 22(2):560-7. PubMed ID: 17035369
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase levels in the drained dialysate reflect the peritoneal solute transport rate: a multicentre study in Japan.
Hirahara I; Inoue M; Umino T; Saito O; Muto S; Kusano E
Nephrol Dial Transplant; 2011 May; 26(5):1695-701. PubMed ID: 20921293
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor-1 and peritoneal transport in peritoneal dialysis patients.
Wadhwa NK; Lin JJ; Parton L; Bereket G; Cabralda T; Suh H
Adv Perit Dial; 1996; 12():33-8. PubMed ID: 8865868
[TBL] [Abstract][Full Text] [Related]
14. Tissue-type plasminogen activator (tPA) and its inhibitor (PAI-1) in patients treated with continuous ambulatory peritoneal dialysis.
Opatrný K; Opatrná S; Vít L; Opatrný K
Am J Nephrol; 1998; 18(3):186-92. PubMed ID: 9627033
[TBL] [Abstract][Full Text] [Related]
15. A Matrix Metalloproteinase-2-Based Nomogram to Assess the Risk of Encapsulating Peritoneal Sclerosis in Peritoneal Dialysis Patients.
Chou CY; Tseng CC; Chen JB; Hung CC; Huang CC
Biomed Res Int; 2021; 2021():6666441. PubMed ID: 33532492
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions.
Opatrna S; Lysak D; Trefil L; Parker C; Topley N
Perit Dial Int; 2012; 32(1):37-44. PubMed ID: 22302924
[TBL] [Abstract][Full Text] [Related]
17. Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-I (PAI-I) levels in plasma and peritoneal effluent in patients on CAPD.
Selgas R; Cuesta MV; Riñon C; Romero JR; de Alvaro F; Bajo MA; Sanchez-Sicilia L
Adv Perit Dial; 1992; 8():160-5. PubMed ID: 1361777
[TBL] [Abstract][Full Text] [Related]
18. Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients.
van Esch S; Zweers MM; Jansen MA; de Waart DR; van Manen JG; Krediet RT
Perit Dial Int; 2004; 24(6):554-61. PubMed ID: 15559485
[TBL] [Abstract][Full Text] [Related]
19. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis.
Pecoits-Filho R; Carvalho MJ; Stenvinkel P; Lindholm B; Heimbürger O
Perit Dial Int; 2006; 26(1):53-63. PubMed ID: 16538876
[TBL] [Abstract][Full Text] [Related]
20. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H
Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
